Why Atrion Is Poised to Outperform

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Atrion (Nasdaq: ATRI  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Atrion and see what CAPS investors are saying about the stock right now.

Atrion facts

Headquarters (founded)	Allen, Texas (1944)
Market Cap	$395.8 million
Industry	Health care supplies
Trailing-12-Month Revenue	$116.1 million
Management	CEO David Battat (since 2011) CFO Jeffery Strickland (since 1997)
Return on Equity (average, past 3 years)	18.1%
Cash / Debt	$38.7 million / $0
Dividend Yield	1.1%
Competitors	Baxter International (NYSE: BAX  ) Covidien (NYSE: COV  ) Teleflex (NYSE: TFX  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 257 members who have rated Atrion believe the stock will outperform the S&P 500 going forward.

Just last month, one of those bulls, fellow Fool Buck Hartzell (TMFBuck), succinctly summed up the outperform case for our community: "Great capital allocators here. Look at their returns on equity. Surprisingly diversified for a small cap company. I like the ownership and the capital allocation decisions. This is a long term hold."

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Atrion may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.